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Abstract
Objective: Patients with early multiple sclerosis (MS) have stereotyped attack severity and recovery. We sought to
determine if polymorphisms in MS susceptibility genes are associated with these attack features or with the risk of a second
attack.
Methods: 503 white subjects evaluated within a year of MS onset were included in the study. The severity of and recovery
from the first two attacks were determined based on published definitions. Seventeen MS susceptibility genes were
genotyped at the UCSF MS Genetics laboratory. Each polymorphism was evaluated in multivariate ordinal models, adjusted
for the other polymorphisms, for its association with attack severity and recovery. We also assessed if these polymorphisms
were associated with increased risk of a second attack.
Results: The MPHOSPH9 polymorphism was associated with greater attack severity (odds ratios [OR]=1.47, 95% CI [1.11,
1.94], p=0.008), while the RGS1 and TNFRSF1A polymorphisms tended to be associated with reduced attack severity. The
CD6 polymorphism tended to be associated with increased odds of worse attack recovery (OR=1.25, 95% CI [0.93, 1.68],
p=0.13). In those who were HLA-DRB1-negative, the EVI5 polymorphism was associated with attacks of less severity; in HLA-
DRB1 positive patients, EVI5 was associated with attacks of greater severity and worse recovery. The IL7R, TNFRSF1A, and
GPC5 polymorphisms tended to be associated with having a second event within a year.
Conclusions: Some MS susceptibility polymorphisms may be associated with attack severity, recovery, or frequency. Further
characterization of these genes may lead to a better understanding of MS pathogenesis and to a more individualized
treatment approach.
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Introduction
While the severity of and recovery from multiple sclerosis (MS)
attacks vary substantially from one person to the next, an
individual patient’s early attacks are likely to be of stereotyped
severity and recovery [1]. In other words, a person who has a
severe first attack is at greater risk of a severe second attack, and a
person who has poor neurologic recovery from the first attack is
more likely to recover poorly from the second attack.
In the past few years, the number of genes that have been
confirmed as important to MS susceptibility has increased
PLOS ONE | www.plosone.org 1 October 2013 | Volume 8 | Issue 10 | e75416substantially [2–13]. Whether these genes are associated with the
clinical phenotype of the disease is less clear. In this preliminary
investigation, we sought to determine if genetic polymorphisms
associated with MS susceptibility are associated with the severity of
and recovery from early attacks of MS or with the risk of a second
attack.
Methods
Ethics statement
This study was approved by the University of California, San
Francisco (UCSF) Committee on Human Research (CHR); each
center contributed data from patients enrolled in Institutional
Review Board-approved studies who had provided written
informed consent. The only study/institution in which minors
were enrolled was at UCSF; in the case of all minors, verbal assent
was provided by the patient and written informed consent was
provided by a parent.
Subjects and sites
White subjects with clinically isolated syndrome (CIS) or
relapsing-remitting MS at five MS centers and from two clinical
trials who were followed prospectively from within a year of
disease onset and had brain magnetic resonance imaging (MRI)
within six months of MS onset. At UCSF, three cohorts were used.
From the UCSF MS Center, data for all children and adult
patients seen within one year of MS onset are prospectively
collected [1]. Clinic visits usually occur every 6 months, and
unscheduled visits occur if a patient has an exacerbation. Subjects
from the atorvastatin or riluzole trials at UCSF were also included
[14,15]. Atorvastatin trial participants were seen within 90 days of
onset and were followed monthly for the first three months and
then every three months for 18 months; unscheduled visits
occurred for relapses. For the riluzole study, which was incomplete
at the time of the data freeze, patients were enrolled within a year
of disease onset and were seen monthly for the first six months,
then every three months for two to three years; additional visits
were scheduled for relapses. At the MS Unit of the Department of
Neurology in Marseille, France, data from a cohort of patients
seen within six months of disease onset who participated in a
prospective natural history study of MS that began in 2000 were
captured using the EDMUS database [16]. Clinic visits and MRIs
were typically scheduled every 3 months during the first year,
every 6 months for the next 3 years, and every year subsequently.
Patients from the Centre Hospitalier de L9Universite ´ de Montreal,
Canada who met the inclusion/exclusion criteria were offered
participation in the study from September, 2007 until March,
2009. Patients were seen every year or more regularly if the disease
was active. Subjects seen at the University of Navarra, Spain who
were seen at MS onset were enrolled in a prospective biomarker
study of MS beginning in 2001 [17]. Subjects were followed at the
clinic every 3 to 6 months after MS onset. Clinical and
demographic data were collected prospectively using the EDMUS
database. At the Hospital Universitario Puerta de Hierro, subjects
with CIS seen within one year of onset underwent neurologic
examination at three months and were followed every six months
unless they had a relapse, in which case they were seen for an
unscheduled visit. The Optic Neuritis Treatment Trial (ONTT)
was a multicenter study that enrolled subjects within the first 8
days of optic neuritis; some had had prior attacks [18]. For
purposes of the current study, those without prior neurologic
symptoms consistent with a previous MS/CIS attack were
excluded. Follow-ups occurred on days 4, 15, and 30, weeks 7,
13, and 19, months 6 and 12, and then yearly [19]. The
Controlled High Risk Avonex Multiple Sclerosis Prevention Study
in Ongoing Neurologic Surveillance (CHAMPIONS) study was an
open-label extension of Controlled High Risk Subjects Avonex
Multiple Sclerosis Prevention Study (CHAMPS) [20,21].
CHAMPS enrolled subjects without a prior episode of neurologic
dysfunction who were seen within 27 days of the onset of
neurologic symptoms consistent with MS and had an abnormal
brain MRI ($2 clinically silent MS-consistent lesions). Subjects
were randomized to weekly intramuscular interferon beta-1a
versus placebo. CHAMPIONS enrolled willing CHAMPS partic-
ipants for ongoing open-label follow-up. Subjects were seen every
6 months in both studies; unscheduled relapse assessments
occurred within seven days of new symptom onset for the
CHAMPS phase of the study, or within 2 weeks in the extension
phase.
Outcomes
Relapses were defined as new or recurring neurological
symptoms referable to the CNS lasting for at least 48 hours after
a remission of 30 days or more since the previous attack in the
absence of fever or known infection. Pseudoexacerbations were
excluded. The severity of and recovery from the first attack were
determined based on definitions derived from previous publications
[1]. Mild first attack severity was defined as FunctionalSystems (FS)
scores of 0 to 1 in one to three FSs, or visual acuity (VA) better than
or equal to 20/40, EDSS score 0 to 1.5 inclusive; moderate severity
was defined as a score of at least 2 but not higher than 2 in one or
two FSs or four or more scores of 1 or VA of 20/50 to 20/190,
EDSS 2.0 to 2.5 inclusive; severe was assigned for relapses
exceeding prior criteria. Recovery was scored using the lowest
EDSS and FS scores between two to 12 months afterthe attack. For
the first attack, recovery was considered complete (no residual
complaint, normal follow-up examination, all FS scores=0, follow-
up EDSS score=0), fair (residual subjective complaint that does
not impairactivity,orat leastoneFS scoreof1 atmostorVA better
or equal to 20/40, follow-up EDSS=1.0 to 1.5), or poor (at least
one FS score of 2 or more or VA of 20/50 or worse).
For the second event, severity was scored the same way if the
pre-event EDSS was 0. When the second event was preceded by
incomplete recovery, the severity was defined as mild (EDSS
increase by 0.5 point, or 1 point change in up to three FS scores),
moderate (EDSS increase by 1 or 2 points, or 2 points change in
up to two FS, or 1 point change in four or more FS), or severe
(exceeding prior criteria). Recovery from the second event was
defined as complete if no residual signs or symptoms remained
above those which were present prior to the attack, fair if EDSS
increased by up to one point or if there was an increase of one
point on one or two FS (e.g. residual subjective complaint or new
residual finding compared to baseline that does not impair
activity), or poor if exceeding prior criteria.
Predictors: genetic polymorphisms
Several genetic polymorphisms outside of the HLA region have
been validated as being associated with the risk of developing MS
[2–13]. For this study, in addition to HLA-DRB1, we selected the 16
non-HLA genes that had been validated as of 2010 (Table 1).
Genotyping was conducted in the laboratory of Dr. Jorge
Oksenberg with TaqMan SNP genotyping assays (Applied Biosys-
tems Inc., Foster City, CA, USA). The following were contained in
every PCR reaction: 10 ng of DNA, 16TaqMan Genotyping
Master Mix, and 16SNP assay (both from Applied Biosystems,
Inc.). An ABI 97000 GeneAmp PCR system (Applied Biosystems,
Inc.) was used for amplification. The following PCR program was
used: 95u Celsius for 10 minutes, then 50 cycles of 95u Celsius for 15
MS Relapse Severity/Recovery: Genetic Predictors
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Sequence Detection System (with SDS 2. software; Applied
Biosystems, Inc.) was used to read the plates. A PCR locus-specific
amplification was used for DRB1, as previously described [9].
Statistics
We dichotomized each gene as having one or two versus no
copies of the risk allele and assessed its association with severity,
recovery, and risk of a second event. We also looked for
interactions (defined by p value for interaction term,0.1) between
HLA-DRB1 and EVI5 and HLA-DRB1 and CD226a because such
interactions have been identified in MS susceptibility studies [7,9].
All genes were studied in multivariate models to assess each
polymorphism’s effect independent of the others.
Because severity and recovery were measured on an ordered,
three-level scale, predictors of these attack features were analyzed
with repeated measures ordinal logistic regression; we used the
Stata ologit command, with the ‘‘vce (cluster)’’ option. We
attempted to confirm the results by assessing the outcomes as
dichotomous using generalized estimating equations with robust
standard errors. To determine the association of polymorphisms
with second attack risk, we used a multivariate Cox proportional
hazards model. The exact date of the second attack could not be
established in most of the ONTT patients who had a second
attack, although a range of possible second attack dates was
available. As such, to approximate an approach from a prior
publication [22], we also conducted a multivariate logistic
regression analysis, adjusted for length of follow-up, in which the
outcome was the binary outcome of a second attack within 1 year
(which could be ascertained for all but four patients).
Results
Patient and attack characteristics
We identified 503 patients (n=199 from UCSF; n=43 from
Marseille; n=36 from Montreal; n=13 from Pamplona; n=60
from Madrid; n=68 from CHAMPIONS; n=84 from ONTT).
The mean age at onset was 3369 years; 359 (71%) were women.
Initial brain MRI showed abnormalities consistent with MS in 459
(91%). Genotyping failure occurred only for IRF8 in one patient.
All subjects had at least one copy of the TYK2 G allele, so we
assessed if two G alleles versus one was associated with the
outcomes. Similarly, no subject had more than one copy of the
TNFRSF1A T allele, so we assessed if one versus no copies of the T
allele was associated with the outcomes. Nearly half the patients
(n=244; 49%) had one or more copies of HLA-DRB1*1501. Allele
frequencies for the non-HLA polymorphisms are presented in
Table 1.
A second attack was experienced by 69% (n=349); mean
follow-up was 6.565.0 years in those who did not have a second
attack. DMT was initiated in 69% (n=345) during the follow-up
period, but only 134 (27%) had received DMT for at least 90 days
immediately preceding the second attack or, if no second attack
occurred, preceding the end of follow-up. Relapse severity and
recovery are presented in Table 2.
Genetic predictors of attack severity
The associations of the polymorphisms with attack severity are
presented in Table 3. The MPHOSPH9 risk allele was associated
with increased odds of more severe events (odds ratio [OR]=1.47,
95% confidence interval [CI] [1.11, 1.94], p=0.008), while the
RGS1 (OR=0.47, 95% CI [0.21, 1.03], p=0.060) and TNFRSF1A
(OR=0.63, 95% [0.40, 1.00]), p=0.050) polymorphisms were
associated with tendencies for reduced attack severity. The
univariate results were similar (Table S1 in File S1), and the
results were not meaningfully different when use of DMT prior to
the attack (or end of the follow-up, when no second attack
occurred), was included in the models (data not shown). When
event severity was dichotomized, there was an additional trend for
IL12A to be associated with an attack being moderate or severe
(Table S2 in File S1). When a more extreme outcome (severe
versus mild or moderate attacks) was assessed (Table S2 in File S1),
there was additionally a strong association between the CD58
polymorphism and reduced odds of a severe attack (OR=0.25,
Table 1. Non-HLA genes associated with multiple sclerosis tested in this study.
Gene
Single Nucleotide
Polymorphism
Minor Allele
(Major Allele)
Number (%) of subjects with one
or two copies of minor allele Risk Allele for MS
CD58 [4,6,10] rs2300747 G (A) 94 (19) A
RGS1 [6,12] rs2760524 A (G) 150 (30) G
EVI5 [2,9] rs10735781 C (G) 419 (83) G
KIF21B [3] rs12122721 A (G) 250 (50) G
IL12A [6,12] rs4680534 C (T) 302 (60) C
TMEM39A [3] rs1132200 A (G) 115 (23) G
IL7R [5,6,10] rs6897932 T (C) 210 (42) C
IL2RA [2,6,7,10] rs2104286 G (A) 184 (37) A
CD6 [6] rs17824933 G (C) 233 (46) G
MPHOSPH9 [12] rs1790100 G (T) 217 (43) G
TNFRSF1A [6] rs4149584 T (C) 41 (8) T
CLEC16A [9,11] rs12708716 G (A) 286 (57) A
CD226a [9,11] rs763361 C (T) 354 (70) T
TYK2 [5,9] rs34536443 C (G) 25 (5) G
IRF8 [6] rs17445836 A (G) 165 (33) G
GPC5 [8] rs727986 C (T) 203 (40) C
doi:10.1371/journal.pone.0075416.t001
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tended to be associated with attacks being severe.
There was an interaction of HLA-DRB1 and EVI5 (p=0.004 for
interaction term). Among those who were HLA-DRB1 negative,
EVI5 was associated with reduced odds of a more severe attack
(OR=0.62, 95% CI [0.43, 0.91], p=0.015) but tended to have
greater odds of a more severe attack in the HLA-DRB1-positive
group (OR=1.54, 95% CI [0.97, 2.45], p=0.068). There was no
strong evidence for interaction between HLA-DRB1 and CD226a
(p= 0.44 for interaction term). The results were similar in models
in which the odds of severe/moderate attacks were ascertained,
although when severe attacks were the outcome, the p value for
the interaction term between HLA-DRB1 and CD226a was 0.060.
CD226a was associated with lower odds of severe attacks in HLA-
DRB1-negative patients (OR=0.56, 95% CI [0.30, 1.05],
p=0.07), while it did not appear to be meaningfully associated
with severity in HLA-DRB1-positive patients (OR=1.34, 95% CI
[0.70, 2.54], p=0.38).
Genetic predictors of attack recovery
Only the CD6 polymorphism tended to be associated with worse
attack recovery (OR=1.25, 95% CI [0.93, 1.68], p=0.13),
although the CIs included 1.0 (Table 3). The results were similar in
univariate models (Table S1 in File S1) or when recovery was
dichotomized into incomplete versus complete (Table S2 in File
S1), or when DMT use was added into the multivariate models
(data not shown).
There was an interaction of HLA-DRB1 and EVI5 in the attack
recovery model (p=0.011 for interaction term). Among those who
were HLA-DRB1 negative, EVI5 did not appear to be substantially
associated with recovery (OR=0.82, 95% CI [0.54, 1.24],
p=0.34), but it was associated with greater odds of worse recovery
in the HLA-DRB1-positive group (OR=1.80, 95% CI [1.16, 2.81],
p=0.009); results were similar when incomplete recovery was the
outcome. There was no strong evidence for interaction between
CD226a and HLA in either recovery model (p value for interaction
term=0.37 for primary model; p=0.61 for incomplete recovery
model).
Genetic predictors of second event risk
Overall, none of the polymorphisms of interest appeared to be
strongly associated with second attack risk, although the CIs were
wide (Table 4). However, there were trends of interest: the
TNFRSF1A polymorphism was associated with increased attack
risk, while the CD58 polymorphism was associated with decreased
risk. There was no strong evidence for interaction between HLA-
DRB1 and EVI5 (p value for interaction term=0.27) or CD226a
(p=0.75). When the odds of a second attack occurring within a
year were evaluated, TNFRSF1A, IL7R, and GPC5 tended to be
associated with increased odds thereof (Table 4). The results were
similar in univariate models (Table S3 in File S1), with IL12A
demonstrating an association with slightly reduced odds of a
second attack within a year.
Discussion
The variability in outcomes between patients with MS leads to
prognostic uncertainty, which causes significant psychological
stress for patients and their caregivers [23,24]. It also makes the
role of the physician more difficult in that for an individual patient,
a plan of care must be made using group-level data. With the
advent of more potent but more risky DMTs for MS, developing
better models for predicting prognosis is imperative so that those
who are unlikely to have bad disease outcomes are not exposed
unnecessarily to hazardous therapies. Genetic polymorphisms
associated with MS are attractive candidate predictors for
inclusion in prognostic models. Other studies have evaluated the
association of MS risk alleles with the rate of MS progression or
risk of conversion from CIS to RRMS and have found little
evidence of such associations [25,26].
Herein, we have the first preliminary evidence that some of the
genes known to increase MS risk may also be associated with the
severity of early attacks or the degree of recovery from them,
although the wide confidence intervals suggest that the without
Table 2. Attack severity and recovery.
Event Characteristic First Event Second Event*
Severity, n (%)**
Mild 226 (45) 128 (47)
Moderate 192 (38) 95 (35)
Severe 85 (17) 48 (18)
Recovery, n (%)***
Complete 282 (58) 151 (56.3)
Fair 151 (31) 84 (31.3)
Poor 54 (11) 33 (12.3)
*While 349 in the overall cohort had a second event during follow-up, of those
in the CHAMPIONS and ONTT cohorts (total n=152, 104 (68%) of whom had a
second attack), second attack severity was not calculable for ONTT patients and
was calculable for 28 (61%) of CHAMPIONS patients who had a second attack.
Second attack recovery was calculable for 34 CHAMPIONS patients and no
ONTT patient; ** could not be characterized for 2 second events among non-
ONTT/non-CHAMPIONS cohorts; *** could not be characterized for 16 first
attacks overall or for 11 second events among non-ONTT/non-CHAMPIONS
cohorts.
doi:10.1371/journal.pone.0075416.t002
Table 3. Association of MS susceptibility genes with attack
severity and recovery (multivariate models).
Gene More severe attacks Worse recovery from attacks
RGS1 0.47 (0.21, 1.03), p=0.060 0.96 (0.29, 3.18), p=0.94
CD6 1.01 (0.76, 1.33), p=0.96 1.25 (0.93, 1.68), p=0.13
MPHOSPH9 1.47 (1.11, 1.94), p=0.008 1.05 (0.78, 1.41), p=0.77
TNFRSF1A 0.63 (0.40, 1.00), p=0.050 0.77 (0.44, 1.34), p=0.35
HLA-DRB1 0.95 (0.71, 1.28), p=0.74 1.10 (0.82, 1.48), p=0.52
CD58 0.43 (0.10, 1.84), p=0.25 0.54 (0.11, 2.64), p=0.45
EVI5 0.97 (0.72, 1.30), p=0.83 1.22 (0.90, 1.65), p=0.20
KIF21B 1.04 (0.58, 1.87), p=0.89 1.11 (0.50, 2.48), p=0.80
IL12A 1.16 (0.87, 1.55), p=0.32 1.03 (0.77, 1.37), p=0.85
TMEM39A 0.82 (0.21, 3.24), p=0.78 0.90 (0.39, 2.11), p=0.82
IL7R 0.91 (0.48, 1.73), p=0.77 0.80 (0.41, 1.59), p=0.53
IL2RA 1.19 (0.63, 2.26), p=0.59 1.38 (0.61, 3.14), p=0.44
CLEC16A 1.28 (0.79, 2.09), p=0.32 0.99 (0.64, 1.52), p=0.96
CD226a 1.09 (0.78, 1.53), p=0.60 1.08 (0.78, 1.51), p=0.64
TYK2 0.86 (0.50, 1.48), p=0.59 1.00 (0.50, 2.01), p=0.99
IRF8 0.94 (0.38, 2.31), p=0.89 0.62 (0.24, 1.61), p=0.32
GPC5 1.03 (0.77, 1.39), p=0.83 1.06 (0.79, 1.44), p=0.69
Results are presented as odds ratios (95% confidence intervals), p values.
doi:10.1371/journal.pone.0075416.t003
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not be over-interpreted. Nonetheless, from a mechanistic stand-
point, the results are intriguing. MPHOSPH9, which has unknown
function [12], was associated with greater attack severity. One
hypothesis regarding its function is that this SNP is associated with
reduced expression of the nearby CDK2AP1 gene, a cell cycle
regulator [27]. RGS1 proteins terminate G-protein signaling and
reduce lymphocyte trafficking; in vitro and in vivo, they are regulated
in part by interferon beta-1b, an MS therapy [28]. It is thus
biologically plausible that the RGS1 risk allele may influence attack
severity. The TNFRSFA1 polymorphism, associated with a
tendency for less severe early attacks, is of functional interest
because the TNFa pathway has been implied in MS pathogenesis.
TNFa inhibitors, used to treat some autoimmune disorders, are
thought to precipitate demyelinating episodes consistent with MS
[6]. There were several genes that had possible relationships with
attack severity when an extreme phenotype (severe versus mild/
moderate attacks) was the outcome. The most convincing
relationship was for CD58, a CD2 ligand expressed on T-cells
that is important to their differentiation and proliferation [4,10].
The CD58 A allele confers greater risk of MS; however, having
one or more copies of the allele was associated with mild or
moderate attacks. This result is somewhat surprising in that CD58
expression, which is increased in remission compared to relapse, is
greater in those with the protective G allele [4]. While these results
need to be confirmed, it may be that the CD58 has different roles
in establishing MS risk or relapse timing and in influencing the
severity of relapses. The gene product of CD6, which tended to be
associated with worse recovery, is involved in continuing the
activation of T cells; in healthy individuals with two copies of the
MS risk allele, CD4+ T cell proliferation is actually reduced [29].
Of interest EVI5, which is associated with lymphoma develop-
ment [13], appeared to be associated with event severity and
recovery, but the direction of the association differed depending
on a person’s HLA-DRB1 status; those who were negative for HLA-
DRB1 had events characterized by less severity, while those who
were positive for HLA-DRB1 had events of greater severity or
worse recovery. The directions of these associations are similar to
those reported for MS susceptibility; this finding highlights the
complexity of analyzing the effects of polymorphisms considering
the likelihood of many unidentified interactions between them
[7,9].
None of the polymorphisms assessed showed a convincing
association with risk of early second attack or of a second attack
overall, although the confidence intervals were too wide to provide
evidence against possibly substantial associations.
The study has some limitations. We restricted the analysis to
white patients to reduce heterogeneity, which reduces generaliz-
ability to other racial groups. We included those evaluated within
a year of onset to minimize recall bias and the inclusion of
pseudoexacerbations in the analysis. However, this decision could
have led to inclusion bias, as subjects who present later could be
different from those who come to medical attention earlier. While
fairly objective, our definitions of severity and recovery still rely on
the EDSS (or its components), which has its own limitations in
precision and responsiveness [30,31]. That the ONTT and
CHAMPIONS datasets were missing information relevant to the
study may have introduced bias in addition to increasing
uncertainty. Because our assessment of these genes was hypoth-
esis-driven and since the study was an exploratory investigation
that was not intended to prove with finality any associations, we
did not correct for multiple comparisons. Rather than focusing
only on p values, we were interested in evaluating the directions
and magnitudes of the effects seen in the context of the plausible
biological connections between the SNPs and MS. Thus, our
results need replication in an independent, larger dataset. It would
also be valuable to evaluate SNPs identified subsequent to the
genotyping done for this study for their association with the
severity, recovery, and risk of second attacks [25].
Table 4. Association of MS susceptibility genes with occurrence of second event (multivariate models).
Gene Second event (OR) within a year* Risk (HR) of second event**
CD58 0.66 (0.17, 2.63), p=0.56 0.53 (0.26, 1.09), p=0.082
IL7R 1.88 (0.73, 4.88), p=0.19 1.41 (0.82, 2.41), p=0.22
TNFRSF1A 1.61 (0.82, 3.18), p=0.17 1.29 (0.88, 1.90), p=0.19
GPC5 1.31 (0.88, 1.95), p=0.19 0.95 (0.75, 1.20), p=0.65
HLA-DRB1 1.10 (0.74, 1.62), p=0.65 1.02 (0.81, 1.29), p=0.88
RGS1 0.57 (0.16, 1.96), p=0.37 0.90 (0.39, 2.06), p=0.80
EVI5 1.09 (0.72, 1.64), p=0.69 1.08 (0.85, 1.38), p=0.53
KIF21B 1.02 (0.44, 2.34), p=0.96 0.97 (0.59, 1.60), p=0.92
IL12A 0.77 (0.52, 1.15), p=0.20 1.03 (0.82, 1.31), p=0.78
TMEM39A 0.56 (0.12, 2.71), p=0.47 1.17 (0.47, 2.91), p=0.74
IL2RA 0.81 (0.31, 2.14), p=0.67 1.05 (0.60, 1.85), p=0.87
CD6 0.82 (0.55, 1.21), p=0.31 1.04 (0.82, 1.31), p=0.77
MPHOSPH9 0.89 (0.60, 1.32), p=0.56 0.99 (0.78, 1.24), p=0.91
CLEC16A 1.20 (0.63, 2.31), p=0.58 0.80 (0.55, 1.16), p=0.24
CD226a 1.00 (0.64, 1.54), p=0.99 1.02 (0.79, 1.32), p=0.88
TYK2 1.14 (0.46, 2.86), p=0.78 1.14 (0.67, 1.93), p=0.63
IRF8 1.33 (0.41, 4.32), p=0.63 1.28 (0.67, 2.45), p=0.45
*missing 4 and **44 ONTT patients.
Results are presented as odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals, p values.
doi:10.1371/journal.pone.0075416.t004
MS Relapse Severity/Recovery: Genetic Predictors
PLOS ONE | www.plosone.org 5 October 2013 | Volume 8 | Issue 10 | e75416Our results support prioritizing investigations of the identified
genes to confirm the associations, to better characterize their role
in MS pathogenesis, to determine if they may provide new
therapeutic targets, and to help guide the use of DMT at the
individual patient level.
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